Michaelis, M. and Bliss, J. and Arnold, S. C. and Hinsch, N. and Rothweiler, F. and Deubzer, H. E. and Witt, O. and Langer, K. and Doerr, H. W. and Wels, W. S. and Cinatl, J. (2008) Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins. Clinical Cancer Research, 14 (20). pp. 6531-6537. ISSN 1078-0432.
|The full text of this publication is not available from this repository. (Contact us about this Publication)|
Neuroblastomas frequently show expression of the epidermal growth factor receptor (EGFR) and may therefore be susceptible to EGFR-targeted therapies. Here, EGFR expression and functionality was investigated in parental chemosensitive neuroblastoma cell lines (UKF-NB-3, IMR-32, NLF, SH-SY5Y) and their cisplatin-resistant sublines (UKF-NB-3rCDDP1000, IMR-32rCDDP1000, NLFrCDDP1000, and SH-SY5YrCDDP500). Moreover, the EGFR antibody cetuximab, the EGFR tyrosine kinase inhibitor Tyrphostin B46, and recombinant EGFR-targeted toxins were investigated for their influence on the viability and growth of neuroblastoma cells.
|Uncontrolled keywords:||neuroblastoma; epithelial growth factor; epithelial growth factor receptor; toxin; chemoresistance|
|Divisions:||Faculties > Science Technology and Medical Studies > School of Biosciences|
|Depositing User:||Sue Davies|
|Date Deposited:||08 Oct 2012 13:52|
|Last Modified:||30 Jan 2013 12:42|
|Resource URI:||http://kar.kent.ac.uk/id/eprint/31386 (The current URI for this page, for reference purposes)|
- Depositors only (login required):